Hologic posted a slight decrease in revenue for the company's fourth quarter, which it attributed to lower demand for its SARS-CoV-2 assays compared with the same period in 2020.
For the quarter (end-September 25), Hologic recorded revenues of $1.317 billion, down 2.3% compared with $1.347 billion in sales in the fourth quarter of 2020. The company's net income also fell, from $493.6 million in 2020 to $328.8 million in 2021.
Hologic saw revenue in its diagnostics business of $836.8 million, down 10.9% compared with sales of $939 million in the fourth quarter of 2020 due to lower sales of COVID-19 assays. Excluding revenues from COVID-19 tests, diagnostics sales grew 5.1% after currency adjustment.
The company's breast health division posted revenue increases of 15.6%, at $334.2 million compared with 2020's $289.2 million.
Going forward into 2022, the company expects to report annual revenue of $3.75 to $4 billion, it said.
